Biogen (BIIB) : Traders are bullish on Biogen (BIIB) as it has outperformed the S&P 500 by a wide margin of 22.68% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 8.52%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 8.98% in the last 1 week, and is up 25.73% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Biogen (NASDAQ:BIIB): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $316.16 and $313.69 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $318.91. The buying momentum continued till the end and the stock did not give up its gains. It closed at $315.96, notching a gain of 0.45% for the day. The total traded volume was 1,358,794 . The stock had closed at $314.56 on the previous day.
The stock has recorded a 20-day Moving Average of 13.14% and the 50-Day Moving Average is 19.93%. Biogen Inc. is up 19.86% in the last 3-month period. Year-to-Date the stock performance stands at 3.14%.
Biogen (BIIB) : Average target price received by Biogen (BIIB) is $349.5 with an expected standard deviation of $44.17. The most aggressive target on the stock is $414, whereas the most downbeat target is $283. 14 financial analysts are currently covering the stock.
Biogen Inc., formerly Biogen Idec Inc., is a global biopharmaceutical company. The Company is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. The Company develops, manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Companys marketed products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, FAMPYRA for multiple sclerosis (MS), ALPROLIX for hemophilia B, and ELOCTATE for hemophilia A, among others. It also collaborates on the development and commercialization of RITUXAN (rituximab), which is a monoclonal antibody for the treatment of non-Hodgkins lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA, which is for the treatment of chronic lymphocytic leukemia.